|
Description: Cerus Corporation is developing technology to inactivate a broad spectrum of pathogens and leukocytes in the three major blood components: platelets,plasma, and red blood cells. This project focuses on advanced development of the pathogen inactivation (PI) technology in red blood cells (RBC) for introduction into military and civilian practice. The approaches described are used to address specific problems applicable to the US civilian and Armed Forces` blood supply.
|
|
| |
| Cerus Corporation |
$4,600 |
|
For-Profit |
Concord,
CA
|
|
|
Citation
|
|
Source:
Appropriations Report Language - Conference
|
|
Reference:
108-622
|
|
Location:
Line 31, Page 257
|
Citation Excerpt: Blood Safety & Decontamination Technology
|
|
